TABLE 2.
Agreement | Groupa | Drug | Growth levelb | Overall absolute (relative) % agreement for the indicated method after the following h of incubation:
|
|||
---|---|---|---|---|---|---|---|
24
|
48
|
||||||
NCCLS | XTT | NCCLS | XTT | ||||
Intraexperimental | 1 | ITC | 0 | 82.9 (99.1) | 90.3 (97.7) | 89.7 (99.4) | 92.5 (99.5) |
1 | 83.2 (98.6) | 77.6 (99.1) | 76.1 (99.5) | 82.0 (98.8) | |||
2 | 69.0 (88.8) | 66.9 (87.6) | 69.8 (95.3) | 72.0 (94.9) | |||
3 | 62.4 (80.2) | 59.1 (73.6) | 65.5 (78.2) | 65.0 (86.7) | |||
4 | 60.8 (71.7) | 63.2 (71.8) | 64.1 (77.0) | 63.5 (70.3) | |||
AMB | 0 | 91.0 (99.8) | 96.1 (99.9) | 90.6 (100) | 95.8 (100) | ||
Interexperimental | 2 | ITC | 0 | 78.3 (97.6) | 75.3 (95.6) | 83.7 (99.4) | 85.6 (99.3) |
1 | 69.6 (95.5) | 74.5 (96.6) | 78.3 (98.9) | 77.0 (98.6) | |||
2 | 65.8 (85.7) | 64.6 (85.3) | 71.5 (94.3) | 68.8 (93.3) | |||
3 | 62.8 (82.2) | 57.7 (75.9) | 67.7 (82.5) | 69.1 (87.8) | |||
4 | 61.9 (73.8) | 58.5 (68.4) | 66.0 (79.3) | 66.8 (77.2) | |||
AMB | 0 | 81.7 (99.0) | 87.9 (99.7) | 78.1 (99.7) | 83.1 (99.7) | ||
3 | ITC | 0 | 54.7 (76.2) | 64.4 (90.9) | 75.4 (91.6) | 87.3 (99.4) | |
1 | 71.2 (99.7) | 74.8 (95.7) | 84.7 (97.6) | 81.0 (97.2) | |||
2 | 65.6 (96.2) | 63.4 (93.1) | 72.3 (99.7) | 67.0 (89.6) | |||
3 | 58.8 (71.4) | 56.0 (80.2) | 62.9 (89.6) | 49.3 (88.9) | |||
4 | 61.7 (64.3) | 61.7 (67.0) | 59.5 (64.8) | 56.1 (78.2) | |||
AMB | 0 | 78.9 (99.7) | 88.2 (100) | 92.4 (100) | 89.6 (100) |
Groups 1 and 2, NCCLSvis and XTTvis, 95% CI limits of absolute agreement ranged from ±3.6 to ±5.6%; group 3, NCCLSsp and XTTsp, 95% CI limits of absolute agreement ranged from ±2.6 to ±11.3%.
Growth levels: 0, no visible growth (≤5% that of growth control); 1 slight growth (6 to 25% that of growth control); 2, prominent reduction of growth (26 to 50% that of growth control); 3, slight reduction of growth (51 to 75% that of growth control); 4, no reduction of growth (76 to 100% of growth control).